216 related articles for article (PubMed ID: 27479788)
1. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
Hankus J; Tomaszewska R
Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
[TBL] [Abstract][Full Text] [Related]
2. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
[TBL] [Abstract][Full Text] [Related]
5. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
6. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry.
Mizutani G; Nakanishi Y; Watanabe N; Honma T; Obana Y; Seki T; Ohni S; Nemoto N
Acta Histochem Cytochem; 2012 Jun; 45(3):167-76. PubMed ID: 22829710
[TBL] [Abstract][Full Text] [Related]
7. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
8. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
9. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
[TBL] [Abstract][Full Text] [Related]
10. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias.
Remes SM; Leijon HL; Vesterinen TJ; Arola JT; Haglund CH
J Histochem Cytochem; 2019 Oct; 67(10):735-743. PubMed ID: 31381461
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the expression of somatostatin receptors by immunohistochemistry in neuroendocrine tumors of the small intestine.
Pol J Pathol; 2020; 71(1):30-37. PubMed ID: 32429652
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
20. Expression of Somatostatin Receptor Subtypes (SSTR-1-SSTR-5) in Pediatric Hematological and Oncological Disorders.
Harda K; Szabo Z; Juhasz E; Dezso B; Kiss C; Schally AV; Halmos G
Molecules; 2020 Dec; 25(23):. PubMed ID: 33297556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
